Improvement in Mucosal Discoid Lupus Erythematosus with Anifrolumab.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llad190
Abstract: Anifrolumab is a fully humanized monoclonal antibody targeting type I interferon receptor recently approved for the treatment of moderate-to-severe systemic lupus erythematous (SLE). In addition to ameliorating systemic lupus activity, anifrolumab has emerged as a… read more here.
Keywords: discoid lupus; improvement mucosal; lupus erythematosus; mucosal ... See more keywords